Tag: DB-1311
Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small...
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
Accelerating the Development of Differentiated ADCs: BioNTech and DualityBio Form Global...
German-based BioNTech and Duality Biologics (Suzhou) Co, a Shanghai-based clinical-stage biotech company, have entered into exclusive license and collaboration agreements for the ongoing development manufacture and globally* commercialize two investigational antibody-drug conjugates (DB-1303 and DB-1311) directed against HER2.
